Featured Research

from universities, journals, and other organizations

Kidneys From Deceased Donors With Acute Renal Failure Expand Donor Pool

Date:
October 2, 2009
Source:
Wake Forest University Baptist Medical Center
Summary:
Kidneys recovered from deceased donors with acute renal failure -- once deemed unusable for transplant -- appear to work just as well as kidneys transplanted from deceased donors who do not develop kidney problems prior to organ donation, according to a new study.

Kidneys recovered from deceased donors with acute renal failure (ARF) – once deemed unusable for transplant – appear to work just as well as kidneys transplanted from deceased donors who do not develop kidney problems prior to organ donation, according to a new study by researchers at Wake Forest University Baptist Medical Center.

The findings, reported in the October issue of Surgery, suggest the possibility of safely expanding the donor kidney pool by at least 10 to 15 percent, potentially making an additional 1,000 kidneys or more per year available to those waiting for a donor organ.

"There is a critical shortage of donor organs and we are continually making efforts to expand the donor pool," said Robert J. Stratta, M.D., professor of surgery and director of transplantation at Wake Forest Baptist and senior investigator on the study. "While kidneys from deceased donors with ARF have been considered unusable in the past, our study shows they can work quite well. The function of the new kidney may be slow or delayed – and patients may have to continue dialysis for a week or two until the kidney is up and running – but that's really the only downside. Choosing to utilize these kidneys will greatly shorten the waiting time for people who are willing to accept a kidney from this kind of donor."

Stratta and colleagues transplanted 25 kidneys from 17 deceased donors with ARF, which is impaired kidney function that can result from many things, including traumatic injury, exposure to medications toxic to the kidneys, infection, dehydration, shock, and the breakdown of muscle fibers. Unlike chronic kidney failure, ARF can often be reversed if the underlying cause is treated or removed, Stratta said.

All of the kidneys were refused by multiple centers before being offered for transplantation at Wake Forest Baptist. The patients receiving the kidneys had an average waiting time of 24 months until a donor kidney was made available to them and each chose to accept the organ. All of the recipients were monitored for at least 11 months post-transplant. At an average follow-up of 20 months, patient and graft survival rates were 100 percent and 92 percent, respectively – comparable, Stratta said, to the outcomes typically seen when healthy deceased donor kidneys are transplanted.

"As long as the donor kidneys are still producing urine and do not have evidence of scarring from pre-existing conditions such as diabetes or a history of high blood pressure, they appear to restore to a healthy condition when transplanted," he said.

"Each transplant center has its own level of comfort regarding the criteria they use to determine what organs they will and will not accept for transplant," Stratta added. "In the past, kidneys from donors with ARF were considered an absolute 'no.' Then they became a relative 'no.' After this study, I think it's safe to say that they are a relative 'yes' – there is a subset of these donor kidneys that can be safely and successfully transplanted with very good short-term results."

Over the last decade, the number of patients waiting for a kidney transplant has outpaced growth in the number of transplants performed each year. Between 1997 and 2006, the number of patients waiting for a kidney transplant increased by 81 percent from 49,208 to 88,877. During the same time, the number of annual kidney transplants performed in the United States increased by only 41 percent from 11,703 to 16,483. This escalating disparity in the number of end stage renal disease patients on the waiting list relative to those actually receiving kidney transplants has been accompanied by a startling increase in the number of deaths while waiting for transplants, from 2,184 in 1997 to 4,456 in 2006. In addition, median waiting times for kidney transplants have doubled in the last decade.

"Now that we know we can successfully transplant these kidneys and they will work just as well as other deceased donor kidneys, it becomes a decision of personal preference – the transplant center's level of comfort with using these kidneys, the patient's preference with accepting the kidney, and the general public's decision on whether or not to donate life," Stratta said.

Co-authors of the study were Jack M. Zuckerman, B.S., Rajinder P. Singh, M.D., Alan C. Farney, M.D., Ph.D., and Jeffrey Rogers, M.D., all of the Medical Center.


Story Source:

The above story is based on materials provided by Wake Forest University Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University Baptist Medical Center. "Kidneys From Deceased Donors With Acute Renal Failure Expand Donor Pool." ScienceDaily. ScienceDaily, 2 October 2009. <www.sciencedaily.com/releases/2009/10/091001101328.htm>.
Wake Forest University Baptist Medical Center. (2009, October 2). Kidneys From Deceased Donors With Acute Renal Failure Expand Donor Pool. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/10/091001101328.htm
Wake Forest University Baptist Medical Center. "Kidneys From Deceased Donors With Acute Renal Failure Expand Donor Pool." ScienceDaily. www.sciencedaily.com/releases/2009/10/091001101328.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins